Global Ascites Market Projected To Grow Radiantly By 2023; Asserts MRFR Unleashing Industry Forecast

Pune, India, January, 2018/MRFR Press Release/- Market Research Future published a Cooked Research Report on “Global Ascites Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Medtronic (Ireland), Abcore, Inc. (California), Fresenius SE & Co. KGaA (Germany), BioVie Inc. (US), PharmaCyte Biotech Inc. (California), Sofinnova, Becton, Dickinson and Company (US), QED Bioscience Inc. (US), GI Supply (US) are some of the prominent players at the forefront of competition in the Global Ascites Market and are profiled in MRFR Analysis. 

Global Ascites Market - Overview

Ascites is an abnormal accumulation of fluid in the abdominal cavity. Liver cirrhosis is the most common cause of ascites. Its presence is a sign of significant portal hypertension. Other less common factors that may contribute to ascites development are heart failure, kidney failure, cancers, and infection in pancreas. Malignant ascites has a characteristic role in the progression of ovarian cancer. Malignancy-related ascites have also been observed in malignancies of breast, lung, pancreas, gastric, and liver. Ascites can be detected by physical examination at a volume greater than 1.5 ascites. For smaller amount of fluid ultrasound, and CT scan are preferred.

The ascites management largely depends upon its cause. For example, peritoneal carcinomatosis or may be treated by chemotherapy, and surgical resection of the cancer, while heart failure related ascites is treated with medical management and dietary restrictions.

Notably, rising prevalence of cirrhosis, improvement in reimbursement policies, and increasing occurrence of cancer are promoting the growth of ascites market globally. Ascites is a major complication of cirrhosis and is also an important landmark of chronic liver disease in the natural history. The rising alcohol consumption directly leads to the rising hospitalized cases and mortality due to alcoholic liver cirrhosis. Rising prevalence of cirrhosis and its related complications directly promotes the growth of ascites market. Despite these drivers, complications associated with ascites treatment may hinder the growth of market.

Global Ascites Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of Ascites appears to be highly competitive and fragmented. With well-established market in the North America region major companies have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other emerging regions as well. Moreover the other small and medium scale players are generating revenue from local market.

Sequana Medical, a Swiss based company involved in manufacturing of medical devices entered into an agreement with Fresenius Medical Care a Germany based medical device company, to commercialize its innovative alfapump system.

Alfapump system product of Sequana Medical is an automated, fully implantable pump system for the administration of ascites.

Under this agreement, Fresenius Medical Care acquired the rights to distribute the alfapump system across various regions such as Europe, Middle East and Africa markets. These distribution are not currently serviced by Sequana Medical’s in these region. The first few countries that will be served by this distribution are Austria, Belgium, the Netherlands and Poland. Under this agreement Fresenius Medical Care will also be involved in collaborative market development and reimbursement programs in these markets.

Furthermore, the company Sequana Medical in November 2015, announced the launch of its next generation product, alfapump with DirectLink Technology. With this DirectLink technology it allows physicians to monitor the alfapump remotely.

Global Ascites Market -

Regional Analysis

The global ascites market is segmented on the basis of regions: America, Europe, Asia Pacific, and the Middle East & Africa. The Americas accounts for the major share of the market owing to the improvement in reimbursement policies, and high healthcare expenditure. Europe accounts for the second largest market, which is followed by Asia Pacific. Rising cases of liver cirrhosis, increasing government support for research & development, and well-developed healthcare infrastructure have driven the ascites market in Europe. In the year 2016, the R&D expenditure in the Pharmaceutical Industry was EUR 35000 million, suggested by European Federation of Pharmaceutical Industries and Association. Asia Pacific is the fastest growing ascites market due to the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.

The global ascites market is expected to reach till USD 2,832.5 million by 2023 at a CAGR of 4.0%.

Report Details @ https://www.marketresearchfuture.com/reports/ascites-market-1909